mifepristone has been researched along with Breast Cancer in 163 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (12.88) | 18.7374 |
| 1990's | 72 (44.17) | 18.2507 |
| 2000's | 41 (25.15) | 29.6817 |
| 2010's | 22 (13.50) | 24.3611 |
| 2020's | 7 (4.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bender, R; Cohen, J; Collins, MA; Fensome, A; Mackner, VA; Miller, LL; Ullrich, JW; Winneker, R; Wrobel, J; Zhang, P; Zhang, Z; Zhu, Y | 1 |
| Allan, G; Chen, X; Demarest, K; Guan, J; Gunnet, J; Jain, N; Kang, FA; Linton, O; Lundeen, S; Sui, Z; Tannenbaum, P; Xu, J; Zhu, P | 1 |
| Ecker, GF; Haslinger, E; Hödl, C; Kunert, O; Raunegger, K; Schramm, HW; Seger, C; Steiner, R; Strauss, WS; Strommer, R; Sturm, S | 1 |
| Goessler, W; Haslinger, E; Hödl, C; Kunert, O; Leitner, A; Saha, P; Schramm, HW; Steiner, R; Strauss, WS | 1 |
| Feng, G; Guo, Q; Hao, YN; Liu, H; Liu, J; Liu, Y; Sun, X; Yang, L; Zhang, CG; Zhao, CC | 1 |
| Barrett, JE; Bartlett, TE; Boggavarapu, NR; Clarke, RB; Dubeau, L; Evans, DG; Evans, I; Gemzell-Danielsson, K; Ghezelayagh, TS; Haran, S; Herzog, C; Howell, SJ; Jones, A; Jones, L; Lalitkumar, PG; Papaikonomou, K; Pashayan, N; Ponandai-Srinivasan, S; Rådestad, AF; Reisel, D; Risques, RA; Simões, BM; Widschwendter, M | 1 |
| Abascal, MF; Abba, MC; Acosta Haab, G; Belizán, JM; Burruchaga, J; Caillet-Bois, I; Castets, A; Elía, A; Fabris, V; Gass, H; Helguero, LA; Lamb, CA; Lanari, C; Liguori, M; Lovisi, S; Martínez-Vazquez, P; Muñoz, J; Novaro, V; Pataccini, G; Rojas, P; Saldain, L; Sánchez, J; Spengler, E; Vanzulli, SI | 1 |
| Brisken, C; Ronchi, C | 1 |
| Adams, KN; Ahmed, SJ; Akaputra, R; Akosman, I; Akya, A; Ali, S; Aminuddin, A; An, B; An, X; Anana, EV; Ao, L; Arany, Z; Arena, R; Azhar, A; Azhar, W; Baasankhuu, A; Bae, WK; Bahar, B; Balaji, L; Barbosa, M; Batchu, UR; Berg, KM; Berlin, N; Berthier, E; Bettiol, AA; Bi, B; Bodie, D; Borges, VF; Borghi-Silva, A; Bowman, CE; Brantly, M; Budhathoki, L; Bukhari, A; Cabeza, M; Cao, J; Cao, Q; Cao, S; Carrasco-Nuñes, N; Caruso, FR; Carvalho, C; Chakrabarty, D; Chandra Mondal, P; Chandran, V; Chang, P; Chase, M; Chauhan, AS; Chauhan, PS; Che, J; Cheemalamarri, C; Chen, D; Chen, H; Chen, J; Chen, Q; Chen, X; Chen, Z; Chetri, BK; Cho, SW; Choi, TI; Chung, HC; Cocchi, MN; Collins, LC; Colombo, N; Come, SE; Custodio, JM; Dai, TY; De La Garza Ramos, R; de Oliveira, CR; Dębczak, A; DeMuri, GP; Deng, J; Deng, K; Dhanani, LY; Diaz, S; Djaharuddin, I; Dong, G; Dong, Q; Donnino, MW; Dwiyanti, R; Elango, KP; Eleswarapu, A; Evans, EGB; Fachri, M; Fang, Y; Fantappiè, G; Farasat, A; Farsida, F; Fathimah, A; Febrianti, A; Feng, S; Fernandes, V; Fernandez Garcia, E; Fleming, GF; Foskett, JK; Fourman, MS; Fu, M; Fu, W; Fukushima, S; Gahlay, GK; Gai, S; Gao, R; Gao, W; Gilbert, DM; Gong, J; Gong, MN; Gong, Z; González-Cavieres, L; Gordon, SE; Goudarzi, F; Goulart, CDL; Greenstein, AE; Grigg, ARC; Grilli, D; Grisham, RN; Grossestreuer, AV; Grzęda, A; Grzegorczyk, A; Gu, J; Guo, H; Gupta, R; Haldar, A; Hamid, Y; Han, HJ; Hancock, CN; Hassan, GW; Hatta, M; He, D; He, F; He, J; Heidarinia, H; Helmchen, G; Herrera-Lavados, C; Hieber, DL; Hoehr, C; Hou, L; Huang, C; Huang, J; Hussain, S; Imaoka, S; Indoliya, Y; Jain, E; Jana, S; Jang, H; Jang, HS; Jara-Quijada, E; Jeacopello, I; Jeung, HC; Jiang, B; Jiang, D; Jiang, G; Jiang, L; Jiang, Q; Jiang, Y; Jiang, Z; Jiao, Z; Jr, JCB; Jung, M; Jung, S; Junita, AR; Kalavathi, A; Kang, X; Kannan, R; Kato, K; Khadka, M; Khan, AR; Khan, I; Khodayari, N; Kim, BJ; Kim, CG; Kim, CH; Kim, D; Kim, H; Kim, HS; Kim, HT; Kim, TS; Kim, YT; King, R; Koh, K; Konkol, M; Koo, DH; Kretzschmar, R; Krop, IE; Kuang, Y; Kubeneck, LJ; Kulkarni, K; Kumar, N; Kunjan, C; Kwon, WS; Lai, C; Lans, A; Lascano, J; Lavania, UC; Lee, CK; Lee, DA; Lee, HS; Lee, J; Lee, KH; Lee, MS; Lee, SW; Lee, UN; Lemus-Mondaca, R; Li, HR; Li, J; Li, Q; Li, X; Li, Y; Li, Z; Liang, H; Liang, Y; Lin, L; Lin, Y; Lipsyc-Sharf, M; Liu, B; Liu, C; Liu, DX; Liu, H; Liu, J; Liu, K; Liu, S; Liu, X; Liu, Z; Locknane, MP; Lorusso, D; Lü, H; Luo, Z; Lv, X; Ma, Y; Mandava, K; Manfrinetti, P; Mao, W; Marques-Sá, J; Masaki, T; Massi, MN; Matsuse, M; Matulonis, UA; Maxwell, CA; McAssey, EV; McManamen, AM; Mehl, RA; Mendes, RG; Meng, Z; Miao, Z; Miller, S; Milovanovic, S; Mishra, SK; Mitra, S; Mitsutake, N; Miyazaki, Y; Moriwaki, S; Mortenson, R; Moskowitz, A; Mudring, AV; Mues Genannt Koers, L; Muhammad, S; Muhimpundu, S; Murapaka, C; Murota, H; Mv, S; Nakazawa, Y; Nam, CM; Natzir, R; Ngo, L; Nguyen, DD; Nie, Y; Nishigori, C; Noji, MC; Notini, L; Oaknin, A; Ogi, T; Oguro, A; Okukawa, K; Olawaiye, AB; Omble, AD; Oso, T; Page, CA; Palma-Acevedo, A; Pani, M; Parikh, SM; Park, J; Park, S; Partridge, AH; Pashova, HI; Paudel, U; Paulssen, E; Payero, L; Peng, M; Peppercorn, JM; Pérez-Won, M; Pitarresi, JR; Pradhan, J; Prevost, D; Primaguna, MR; Puvvada, N; Qian, D; Rajaure, YS; Rajca, A; Rajput, N; Rana, SR; Rangan, L; Ranjbarian, P; Redd, PS; Ren, T; Rha, SY; Riley, L; Romano, M; Rong, X; Rosenberg, SM; Rostamian, M; Rothwell, KA; Ru, S; Ruddy, KJ; Rustgi, AK; Salam, A; Sankaran, S; Santoso, A; Saravanakumar, P; Satheeshkumar, K; Schapira, L; Schulz, K; Senapati, A; Senju, C; Sharma, P; Shelke, RG; Shen, F; Shen, X; Shen, Y; Sheteiwy, MS; Shetty, PR; Shi, L; Shi, MM; Shiigi, H; Shimada, M; Shinkawa, VAM; Shtender, V; Siswanto, FM; Smetana, V; Snow, C; Sridiana, E; Stephenson, MW; Stoll, S; Su, X; Sun, S; Sun, XF; Surapaneni, JR; Suri, K; Świątek, Ł; Syukri, A; Tabilo-Munizaga, G; Takezawa, MG; Tamimi, RM; Tamura, A; Tanaka, K; Tang, M; Tao, Y; Tateishi, S; Thapa, B; Theberge, AB; ThomasArrigo, LK; Thongpang, S; Tiwari, M; Tong, Q; Totton, RR; Tripathi, RD; Tsujimoto, M; Tu, WC; Tudor, IC; Tyskiewicz, K; Ubaidah, FM; Ulhassan, Z; Utani, A; Van Gorp, T; Veerapandian, V; Vennila, KN; von Gunten, U; Wagle, N; Waks, AG; Wald, ER; Wang, B; Wang, D; Wang, H; Wang, L; Wang, W; Wang, X; Wang, Y; Wang, Z; Warner, E; Waterhouse, GIN; Weiss, J; Weissenrieder, JS; Wellen, KE; Wu, JY; Xiang, W; Xiao, S; Xie, Q; Xu, F; Xu, TW; Xu, Y; Yan, B; Yan, JM; Yang, D; Yang, P; Yang, S; Yang, W; Yao, Y; Yassari, R; Yong, Q; Yu, H; Yu, Z; Yun, UJ; Zagotta, WN; Zang, DY; Zanudo, JGT; Zeng, A; Zhang, H; Zhang, R; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YT; Zhao, C; Zhao, J; Zhong, S; Zhou, F; Zhou, W; Zhou, Y | 1 |
| Bast, RC; Cheon, DJ; Cho, CH; Coffey, DM; DeMayo, FJ; Emerson, RE; Fernández, FM; Godwin, AK; Hawkins, SM; Karpf, AR; Kim, J; Kim, O; Kwon, SY; Lydon, JP; Miller, KD; Nephew, KP; Park, EY; Quilliam, LA; Shin, S; Shin, YH; Sood, AK; Widschwendter, M | 1 |
| Bosland, MC; Clare, SE; Helenowski, I; Hosseini, O; Khan, SA; Kim, JJ; Lee, O; Patel, P; Schipma, MJ; Shidfar, A; Wang, M; Xuei, X | 1 |
| Abba, MC; Alvarez, M; Elia, A; Gass, H; Gibbons, L; Gonzalez, P; He, X; Hewitt, S; Lanari, C; Martínez, P; May, M; Molinolo, A; Perou, CM; Rojas, PA; Sequeira, GR | 1 |
| Allen, MC; Bucca, G; Falcinelli, M; Flaherty, RL; Flint, MS; Hesketh, A; Intabli, H; Patel, BA; Smith, CP | 1 |
| Baker, ME; Ellies, LG; Friedman, B; Kanter, J; Tsien, RY; Weinstain, R | 1 |
| Choi, YH; Jang, JH; Kim, SH; Kwon, TK; Lee, TJ; Min, KJ; Park, EJ; Um, HJ; Woo, SM | 1 |
| Colombo, L; Lamb, C; Lanari, C; May, M; Molinolo, A; Rojas, P; Sequeira, G; Vanzulli, SI | 1 |
| Conzen, SD; Di Rienzo, A; Fleming, GF; Maranville, JC; Nanda, R; Skor, MN | 1 |
| Fan, P; Jordan, VC; Sweeney, EE | 1 |
| Cong, MH; Sun, JZ; Tian, XS; Wu, GJ; Zhou, WH | 1 |
| Cohen, P; Di Pietro, A; Dumontet, C; Honorat, M; Lin, V; Mesnier, A; Payen, L | 1 |
| Harkins, RN; Jin, F; Levitsky, K; Meurer-Ogden, JA; Szymanski, P | 1 |
| Azcoitia, I; Garcia-Segura, LM; Yague, JG | 1 |
| Adam, G; Cahill, MA; Fehm, T; Mueck, AO; Neubauer, H; Seeger, H; Solomayer, E; Wallwiener, D | 1 |
| Aligiannis, N; Kassi, E; Moutsatsou, P; Papoutsi, Z; Pratsinis, H; Sourlingas, TG; Spiliotaki, M | 1 |
| Edwards, DP; Holley, AK; Jenkins, JT; Kiningham, KK; Moore, MR; Spitz, DR | 1 |
| Cao, M; Chen, J; Dong, DD; He, X; Li, K; Liu, J; Yang, H; Ye, SR; Yie, SM | 1 |
| Alles, MC; Blazek, K; Caldon, CE; Clarke, CL; Cowley, MJ; Daly, RJ; Graham, JD; Hilton, HN; Kalyuga, M; Kaplan, W; Lee, HJ; Musgrove, EA; Naylor, MJ; Ormandy, CJ | 1 |
| Arnoni, MV; Lanari, C; Novaro, V; Polo, ML; Riggio, M; Wargon, V | 1 |
| Huang, J; Huang, Y; Xiao, J; Zhang, X; Zhang, Y | 1 |
| Dotan, N; Mahajna, J; Wasser, SP | 1 |
| Fjelldal, R; Moe, BT; Sager, G; Ørbo, A | 1 |
| Amazit, L; Bellance, C; Guiochon-Mantel, A; Khan, JA; Lombès, M; Loosfelt, H | 1 |
| Benad, P; Hofbauer, LC; Rachner, TD; Rauner, M | 1 |
| Bulun, SE; Coon, JS; Dai, Y; Huang, L; Kim, JJ; Monsivais, D; Navarro, A; Owen, JK; Roqueiro, D; Xie, A; Yin, P | 1 |
| Dohn, MR; Huang, S; Jackson, WH; LeRoith, D; Marrero, M; Periyasamy-Thandavan, S; Schoenlein, PV; Singer, A; Takhar, S; Thangaraju, M; Welborn, AE | 1 |
| Jansson, A; Sivik, T | 1 |
| Bellance, C; Guiochon-Mantel, A; Khan, JA; Lombès, M; Loosfelt, H | 1 |
| Dong, JT; Fu, L; Fu, X; Li, M; Ma, G; Sun, X; Zhang, B; Zhao, D; Zhu, Z | 1 |
| Brandhagen, BN; Goyeneche, AA; Telleria, CM; Tieszen, CR; Tracy, MS; Ulmer, TM | 1 |
| Watanabe, ME | 1 |
| Ahola, TM; Aksenov, N; Pennanen, P; Purmonen, S; Tuohimaa, P; Ylikomi, T; Zhuang, YH | 1 |
| Lanari, C; Molinolo, AA | 1 |
| Charreau, EH; Coso, OA; Elizalde, PV; Kornblihtt, AR; Labriola, L; Pecci, A; Proietti, CJ; Salatino, M | 1 |
| Agoulnik, IU; Amrikachi, M; Ayala, GE; Bingman, WE; Krause, WC; Rahman, HT; Weigel, NL | 1 |
| Barrett, JT; El Etreby, F; Hou, M; Kallab, AM; Liang, Y; Schoenlein, PV | 1 |
| Cui, X; Hopp, TA; Lazard, Z; Lee, AV; Zhang, P | 1 |
| Bray, JD; Lyttle, CR; Winneker, RC; Zhang, Z | 1 |
| Altmeyer-Morel, S; Chevillard, S; Lebeau, J; Lectard, B; Levalois, C; Ory, K; Vares, G | 1 |
| Barrett, JT; Delk, JN; Gaddy, VT; Kallab, AM; Porter, AG; Schoenlein, PV | 1 |
| Bottino, MC; Efeyan, A; Fabris, V; Gorostiaga, MA; Helguero, LA; Lamb, CA; Lanari, C; Molinolo, A; Sanjuan, N; Simian, M; Soldati, R | 1 |
| Augustowska, K; Gregoraszczuk, EL; Krzysiek, J; Milewicz, T; Ryś, J; Sztefko, K | 1 |
| Bonafé, N; Chambers, SK; Flick, M; Savlu, A; Toy, EP; Zeiss, C; Zheng, W | 1 |
| Hyder, SM; Liang, Y; Nawaz, Z; Wu, J | 1 |
| Calaf, GM | 1 |
| Librach, CL; Xiao, R; Yie, SM | 1 |
| Marx, J | 1 |
| Kim, Y; Lee, EY; Lee, WH; Li, Y; Lin, SC; Poole, AJ | 1 |
| Barrett, JT; Gaddy, VT; Ganapathy, V; Hou, M; Johnson, M; Kallab, A; Lewis, J; Samaddar, JS; Schoenlein, PV; Thangaraju, M | 1 |
| Leo, JC; Lin, VC | 1 |
| Besch-Williford, C; Brekken, RA; Hyder, SM; Liang, Y | 1 |
| Alban, P; Dinda, S; Hurd, C; Jhanwar, SC; Khattree, N; Moudgil, VK; Nag, K | 1 |
| Coutts, A; Murphy, LC; Murphy, LJ | 1 |
| Heikinheimo, O | 2 |
| Serfaty, D | 1 |
| Archer, TK; Mymryk, JS | 1 |
| Di Lorenzo, D; Kaufmann, G; Oettel, M; Sobek, L | 1 |
| Alkhalaf, M; Coutts, A; Dotzlaw, H; Haddad-Alkhalaf, B; Murphy, LC | 1 |
| Briggs, J; Donaldson, K; McMaster, D | 1 |
| Groshong, SD; Horwitz, KB; Miller, LA; Powell, RL; Sartorius, CA; Takimoto, GS; Tung, L | 1 |
| Oh-ishi, S | 1 |
| Musgrove, EA; Sutherland, RL | 1 |
| Weiss, BD | 1 |
| Beck, CA; Edwards, DP; Nordeen, SK; Weigel, NL | 1 |
| Beck, CA; Bona, BJ; Edwards, DP; Estes, PA; Muro-Cacho, CA; Nordeen, SK | 1 |
| Horwitz, KB; Sartorius, CA; Takimoto, GS; Tung, L | 1 |
| Bona, BJ; Edwards, DP; Lieberman, BA; Nordeen, SK | 1 |
| Lynch, M; Martin, JH; van den Berg, HW | 1 |
| Manning, DL; Nicholson, RI | 1 |
| Dickson, RB; Lippman, ME; Shi, YE; Sobel, ME; Thompson, EW; Torri, J; Yamada, Y; Yieh, L | 1 |
| Catherino, WH; Jeng, MH; Jordan, VC | 1 |
| Hamilton, JA; Lee, CS; Musgrove, EA; Sutherland, RL; Sweeney, KJ; Watts, CK | 1 |
| Jeng, MH; Jordan, VC; Langan-Fahey, SM | 1 |
| Joosten, JW; Kloosterboer, HJ; Schoonen, WG | 1 |
| Beck, CA; Edwards, DP; Weigel, NL; Zhang, Y | 1 |
| Kettel, LM | 1 |
| Beck, S; Hackenberg, R; Hannig, K; Schmidt-Rhode, P; Scholz, A; Schulz, KD | 1 |
| Figg, WD; Sartor, O | 1 |
| Daxenbichler, G; Hofstädter, F; Marth, C; Müller-Holzner, E; Zeimet, AG | 1 |
| Fritzemeier, KH; Michna, H; Nishino, Y; Parczyk, K; Schneider, MR | 1 |
| Eisenhauer, EA; Fisher, B; Norris, B; Panasci, L; Perrault, D; Pritchard, KI; Vandenberg, T | 1 |
| Baker, C; Hawkins, P; Norris, B; Quinn, PG; Sheridan, PL; Wei, LL | 1 |
| Cornish, AL; Lee, CS; Musgrove, EA; Sutherland, RL; Swarbrick, A | 1 |
| Van Look, PF; von Hertzen, H | 1 |
| Gurpide, E; Markiewicz, L | 1 |
| Grimison, B; Groshong, SD; Horwitz, KB; Langan, TA; Lange, CA; Owen, GI; Schauer, IE; Sclafani, RA; Todd, MC | 1 |
| Baulieu, EE | 1 |
| London, SN; Mahajan, DK | 1 |
| Hyder, SM; Murthy, L; Stancel, GM | 1 |
| Brouwer, A; Kuil, CW; van der Burg, B; van der Saag, PT | 1 |
| Borras, M; Lacroix, M; Leclercq, G; Legros, N | 1 |
| Kimmick, GG; Muss, HB | 1 |
| El Etreby, MF; Liang, Y | 1 |
| Benet, LZ; Jang, GR | 1 |
| Diamandis, EP; Grass, L; Jenkins, DJ; Kendall, CW; Rosenberg, RS | 1 |
| Budel, V; Cahen, P; Chaboteaux, C; Darro, F; Decaestecker, C; Kiss, R; Leblond, B; Nogaret, JM; Pétein, M; Pourrias, B; Ramos, C; Schoofs, A; Vianna, A | 1 |
| El Etreby, MF; Liang, Y; Schoenlein, PV; Wrenn, RW | 1 |
| Cabot, MC; Giuliano, AE; Han, TY; Liu, YY; Lucci, A | 1 |
| Alalami, O; Martin, JH; van den Berg, HW | 1 |
| Alban, P; Dinda, S; Hurd, C; Khattree, N; Moudgil, VK; Nag, K | 1 |
| Archer, TK; Fryer, CJ; Garabedian, MJ; Kinyamu, HK; Rogatsky, I | 1 |
| Arcuri, F; Carducci, A; Cintorino, M; Paulesu, L; Ricci, C; Runci, Y; Sestini, S | 1 |
| Diamandis, EP; Grass, L; Jenkins, DJ; Magklara, A; Rosenberg Zand, RS | 1 |
| Boettger-Tong, H; Chiappetta, C; Huang, JC; Hyder, SM; Mäkelä, S; Nawaz, Z; Stancel, GM | 1 |
| Vastag, B | 1 |
| Bain, DL; Graham, JD; Horwitz, KB; Jackson, TA; Richer, JK; Tung, L | 1 |
| Allan, GF; Campen, CA; Combs, DW; Haynes-Johnson, D; Hodgen, G; Hutchins, A; Kiddoe, M; Kraft, P; Lai, M; Lombardi, E; Palmer, S; Pedersen, P; Rybczynski, P | 1 |
| Brickley, DR; Conzen, SD; Mikosz, CA; Moran, TW; Sharkey, MS | 1 |
| Chiappetta, C; Hyder, SM; Stancel, GM | 1 |
| Alban, P; Dinda, S; Hurd, C; Khattree, N; Moudgil, VK | 1 |
| Aw, SE; Lin, VC; Ng, EH; Tan, MG | 1 |
| Beck, CA; Edwards, DP | 1 |
| Distler, W; Vering, A | 1 |
| DeMarzo, AM; Edwards, DP; Nordeen, SK; Oñate, SA | 1 |
| Altmann, M; Beck, CA; Christensen, K; Edwards, DP; Estes, PA; Prendergast, P; Weigel, NL | 1 |
| Regelson, W | 1 |
| Monet, JD; Thomas, M | 1 |
| Clarke, CL; Kelly, PA; Ormandy, CJ; Sutherland, RL | 1 |
| Horwitz, KB | 2 |
| Findlay, DM; Kurokawa, M; Michelangeli, VP | 1 |
| Lee, CS; Musgrove, EA; Sutherland, RL | 1 |
| Katzenellenbogen, BS; Keith, D; Read, LD; Slamon, DJ | 1 |
| Bircher, JA; Hathaway, LD; Moore, MR | 1 |
| Anderson, C; Coles, P | 1 |
| Bocquel, MT; Chambon, P; Gronemeyer, H; Ji, JW; Meyer, ME; Pornon, A | 1 |
| Dauvois, S; Dumont, M; Haagensen, DE; Labrie, F; Simard, J | 1 |
| Lamberts, SW | 1 |
| Bakker, GH; De Jong, FH; Foekens, JA; Klijn, JG; Portengen, H; Setyono-Han, B | 1 |
| Bader, C; Monet, JD; Thomas, M | 1 |
| Hagley, RD; Hissom, JR; Moore, MR | 1 |
| Carlson, KE; Coppey, M; Katzenellenbogen, JA; Magdelenat, H | 1 |
| Chalbos, D; Chambon, M; Rochefort, H; Vial, HJ | 1 |
| Bowden, RT; Hissom, JR; Moore, MR | 2 |
| Alexieva-Figusch, J; Bakker, GH; de Jong, FH; Klijn, JG; Lamberts, SW; Rodenburg, CJ | 1 |
| Greene, GL; Katzenellenbogen, BS; Read, LD | 1 |
| Assailly, J; Bader, CA; Brami, M; Dautigny, N; Monet, JD; Thomas, M; Ulmann, A | 1 |
| Edwards, DP; Elashry-Stowers, D; Speers, WC; Zava, DT | 1 |
| Moore, MR | 1 |
| Bagchi, MK; Edwards, DP; Elliston, JF; O'Malley, BW; Tsai, MJ; Tsai, SY | 1 |
| Bell, GI; Dubik, D; Murphy, LC; Murphy, LJ; Shiu, RP | 1 |
| Baudot, N; Chomette, G; Fournier, S; Gompel, A; Kuttenn, F; Malet, C; Mauvais-Jarvis, P; Mietze, V; Spritzer, P | 1 |
| Cavalie, G; Grenier, J; Khalaf, S; Maudelonde, T; Pujol, H; Rochefort, H; Romieu, G; Ulmann, A | 1 |
| Greene, GL; Katzenellenbogen, BS; Miller, JS; Read, LD; Snider, CE | 1 |
| Bardon, S; Derocq, D; Gill, PG; Rochefort, H; Vignon, F | 1 |
| Bardon, S; Montcourrier, P; Rochefort, H; Vignon, F | 1 |
| d'Arville, CN; Horwitz, KB; Sedlacek, SM; Wei, LL | 1 |
| Katzenellenbogen, BS; Mullick, A | 1 |
| Bardon, S; Chalbos, D; Rochefort, H; Vignon, F | 1 |
24 review(s) available for mifepristone and Breast Cancer
| Article | Year |
|---|---|
Progesterone receptors--animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer.
Topics: Animals; Breast; Breast Neoplasms; Disease Models, Animal; Female; Humans; Mifepristone; Progestins; Receptors, Progesterone | 2002 |
[Multiple usages for antiprogestins].
Topics: Abortifacient Agents, Steroidal; Abortion, Therapeutic; Breast Neoplasms; Female; Hormone Antagonists; Humans; Male; Meningeal Neoplasms; Meningioma; Mifepristone; Neoplasms, Hormone-Dependent; Pregnancy; Progestins; Receptors, Progesterone | 1994 |
[RU 486: current and potential indications. Great expectations and strong resistance].
Topics: Abortion, Induced; Breast Neoplasms; Contraceptives, Postcoital, Synthetic; Female; Humans; Labor, Induced; Meningeal Neoplasms; Mifepristone; Ovulation; Pregnancy | 1995 |
Normal and stable transfected cancer cell lines: tools for a screening of progestogenic, antiprogestogenic and antiglucocorticoid substances.
Topics: Alkaline Phosphatase; Animals; Breast Neoplasms; Humans; Liver Neoplasms, Experimental; Mifepristone; Molecular Biology; Orosomucoid; Progestins; Receptors, Progesterone; Tumor Cells, Cultured | 1994 |
Regulation of gene expression in T-47D human breast cancer cells by progestins and antiprogestins.
Topics: Breast Neoplasms; Cell Division; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Genes, fos; Genes, jun; Genes, myc; Gonanes; Humans; Medroxyprogesterone Acetate; Mifepristone; Neoplasm Proteins; Progestins; Transforming Growth Factors; Tumor Cells, Cultured | 1994 |
[Pharmacological mechanism of action and development of anti-steroid hormones].
Topics: Androgen Antagonists; Animals; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Male; Mifepristone; Progesterone; Prostatic Neoplasms | 1994 |
RU 486. The progesterone antagonist.
Topics: Abortion, Induced; Animals; Antineoplastic Agents; Breast Neoplasms; Cervix Uteri; Female; Humans; Meningioma; Mifepristone; Pregnancy; Progesterone | 1993 |
Clinical applications of the antiprogestins.
Topics: Abortifacient Agents, Steroidal; Breast Neoplasms; Clinical Trials as Topic; Contraceptives, Oral, Synthetic; Cushing Syndrome; Endometriosis; Endometrium; Female; Hormone Antagonists; Humans; Leiomyoma; Meningeal Neoplasms; Meningioma; Menstrual Cycle; Mifepristone; Pregnancy; Pregnancy, Ectopic; Premenstrual Syndrome; Progestins; Uterine Neoplasms | 1995 |
Mifepristone: antineoplastic studies.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Hormone Antagonists; Humans; Meningeal Neoplasms; Meningioma; Mifepristone | 1996 |
Antiprogestin-progesterone interactions.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Gonanes; Hormone Antagonists; Humans; Mice; Mifepristone; Progesterone | 1996 |
Clinical uses of antiprogestogens.
Topics: Abortion, Induced; Antineoplastic Agents; Breast Neoplasms; Contraception; Contraceptives, Oral, Synthetic; Endometrial Neoplasms; Endometriosis; Estrenes; Female; Gonanes; Humans; Labor, Induced; Mifepristone; Pregnancy; Pregnancy Trimester, Second; Progestins; Prostaglandins; Receptors, Progesterone | 1995 |
RU 486 (mifepristone). A short overview of its mechanisms of action and clinical uses at the end of 1996.
Topics: Animals; Breast Neoplasms; Contraceptives, Oral, Synthetic; Female; Fertility; Glucocorticoids; Hormone Antagonists; Humans; Menstruation-Inducing Agents; Mifepristone; Pregnancy; Progesterone | 1997 |
Mifepristone (RU486): a review.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Animals; Breast Neoplasms; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital, Synthetic; Endometriosis; Female; Humans; Leiomyoma; Mifepristone; Pregnancy; Uterine Neoplasms | 1997 |
Endocrine therapy in metastatic breast cancer.
Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Gonadotropin-Releasing Hormone; Growth Substances; Hormone Antagonists; Humans; Menopause; Middle Aged; Mifepristone; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Palliative Care; Progestins; Receptors, Estrogen; Receptors, Growth Factor; Receptors, Progesterone; Tamoxifen | 1998 |
Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.
Topics: Abortifacient Agents; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Contraceptives, Postcoital, Synthetic; Endometriosis; Estrenes; Female; Gonanes; Hormone Antagonists; Humans; Mifepristone; Progestins | 1997 |
Regulation of vascular endothelial growth factor expression by estrogens and progestins.
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Hormone Antagonists; Humans; Leiomyoma; Lymphokines; Mifepristone; Progestins; Receptors, Estrogen; RNA, Messenger; Signal Transduction; Transcription, Genetic; Uterine Neoplasms; Uterus; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?
Topics: Animals; Breast Neoplasms; Cell Division; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Histone Acetyltransferases; Humans; Mifepristone; Nuclear Receptor Co-Repressor 2; Nuclear Receptor Coactivator 1; Receptors, Estrogen; Receptors, Progesterone; Repressor Proteins; Tamoxifen; Transcription Factors | 2000 |
Progesterone receptors in breast cancer.
Topics: Animals; Breast Neoplasms; DNA-Binding Proteins; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Mifepristone; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphorylation; Progesterone; Protein Conformation; Protein Processing, Post-Translational; Receptors, Glucocorticoid; Receptors, Progesterone; Regulatory Sequences, Nucleic Acid; Signal Transduction; Tumor Cells, Cultured | 1992 |
[Progesterone antagonists--pharmacology and perspectives of use].
Topics: Abortion, Induced; Animals; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Infant, Newborn; Luteal Phase; Mifepristone; Neoplasms, Hormone-Dependent; Pregnancy; Progesterone; Tumor Cells, Cultured | 1992 |
RU 486: how abortion politics have impacted on a potentially useful drug of broad medical application.
Topics: Abortion, Induced; Biomedical Research; Breast Neoplasms; Female; Humans; Internationality; Legislation, Drug; Mifepristone; Patient Advocacy; Politics; Pregnancy; Risk Assessment; United States; United States Food and Drug Administration | 1992 |
The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?
Topics: Animals; Breast; Breast Neoplasms; DNA; Down-Regulation; Female; Humans; Mifepristone; Progesterone; Receptors, Progesterone; Transcription, Genetic; Tumor Cells, Cultured | 1992 |
[Oncological and endocrine administration of the antiprogestagen RU 486].
Topics: Adrenocortical Hyperfunction; Breast Neoplasms; Female; Humans; Meningeal Neoplasms; Meningioma; Mifepristone | 1990 |
Hormone dependence of breast tissue estradiol and progesterone interaction.
Topics: 17-Hydroxysteroid Dehydrogenases; Animals; Breast; Breast Neoplasms; Cells, Cultured; Estradiol; Estrenes; Female; Humans; Mice; Mifepristone; Neoplasms, Hormone-Dependent; Progesterone; Reference Values | 1987 |
Progestin action and progesterone receptor structure in human breast cancer: a review.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Affinity Labels; Animals; Antibodies, Monoclonal; Breast Neoplasms; Cells, Cultured; Chickens; Chromatography, DEAE-Cellulose; Estrenes; Female; Humans; Lipid Metabolism; Mammary Neoplasms, Experimental; Mifepristone; Molecular Weight; Neoplasms, Hormone-Dependent; Oviducts; Progestins; Rats; Receptor, Insulin; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Progesterone | 1985 |
4 trial(s) available for mifepristone and Breast Cancer
| Article | Year |
|---|---|
Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
Topics: Breast Neoplasms; Epigenesis, Genetic; Female; Humans; Mifepristone; Mutation; Progesterone; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms | 2022 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Acute Kidney Injury; Adult; Aged; Albumins; Alloys; Amides; Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bioaccumulation; Blood Glucose; Brain; Brassica napus; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Catalysis; Child; China; Chlorides; Chlorine; Chromium; Chronic Disease; Cohort Studies; Copper; Corrosion; COVID-19; Creatinine; Dermatitis; Diabetes Mellitus; Diazepam; Disease-Free Survival; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Dyspnea; Electron Spin Resonance Spectroscopy; Environmental Monitoring; Escherichia coli; Escherichia coli Infections; Esophageal Neoplasms; Esophagogastric Junction; Estradiol; Exercise Test; Exercise Tolerance; Female; Ferric Compounds; Fishes; Food Chain; gamma-Aminobutyric Acid; Genomics; Halogenation; HEK293 Cells; Hemolysis; Heterocyclic Compounds; Hospitalization; Humans; Hydrogen Peroxide; Hyperglycemia; Introns; Iron; Kidney; Kinetics; Laboratories; Limit of Detection; Lipopolysaccharides; Liver Neoplasms; Magnesium; Male; Mammals; Materials Testing; Mercury; Metal-Organic Frameworks; Methylmercury Compounds; Mice; Microscopy, Electron, Scanning; Mifepristone; Minerals; Molecular Weight; Mutation; Nanoparticles; Neuroprotection; NF-kappa B; Nitrates; Nitrogen; NLR Family, Pyrin Domain-Containing 3 Protein; Orthopedics; Ovarian Neoplasms; Ovariectomy; Oxidation-Reduction; Oxidative Stress; Oxygen; Oxygen Consumption; Paclitaxel; Phenols; Progesterone; Prospective Studies; Proteins; Protons; Pulmonary Disease, Chronic Obstructive; Ramucirumab; Rats; Receptor, ErbB-2; Respiratory Function Tests; Retrospective Studies; Saliva; SARS-CoV-2; Seeds; Sesbania; Shock, Septic; Silicon Dioxide; Sleep; Soil; Specimen Handling; Spectroscopy, Mossbauer; Spin Labels; Staphylococcus aureus; Stomach Neoplasms; Streptococcus mutans; Thiamine; Toll-Like Receptor 2; Toll-Like Receptor 4; Trastuzumab; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Ubiquitin-Protein Ligases; Water; Water Pollutants, Chemical; Water Purification; Xeroderma Pigmentosum; Zebrafish | 2023 |
Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Hormone Antagonists; Humans; Liver Neoplasms; Middle Aged; Mifepristone; Neoplasm Recurrence, Local | 1996 |
The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial.
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrenes; Female; Glucocorticoids; Humans; Mifepristone; Neoplasm Metastasis; Time Factors | 1987 |
135 other study(ies) available for mifepristone and Breast Cancer
| Article | Year |
|---|---|
New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles.
Topics: Alkaline Phosphatase; Animals; Binding, Competitive; Biological Assay; Breast Neoplasms; Cyclohexanes; Decidua; Female; Humans; Indoles; Inhibitory Concentration 50; Rats; Receptors, Progesterone; Structure-Activity Relationship; Tumor Cells, Cultured | 2002 |
Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists.
Topics: Alkaline Phosphatase; Breast Neoplasms; Cell Line, Tumor; Enzyme Induction; Female; Genes, Reporter; Hormone Antagonists; Humans; Mifepristone; Receptors, Glucocorticoid; Receptors, Progesterone; Stereoisomerism; Steroids; Structure-Activity Relationship | 2007 |
Syntheses and antigestagenic activity of mifepristone derivatives.
Topics: Alkaline Phosphatase; Breast Neoplasms; Cell Line, Tumor; Female; Hormone Antagonists; Humans; Mifepristone; Models, Molecular; Neoplasms, Hormone-Dependent; Receptors, Progesterone; Regression Analysis; Structure-Activity Relationship | 2009 |
Synthesis, in vitro progesterone receptors affinity of gadolinium containing mifepristone conjugates and estimation of binding sites in human breast cancer cells.
Topics: Binding Sites; Breast Neoplasms; Cell Line, Tumor; Coordination Complexes; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Mifepristone; Receptors, Progesterone | 2010 |
Paclitaxel-based supramolecular hydrogel loaded with mifepristone for the inhibition of breast cancer metastasis.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Drug Carriers; Drug Liberation; Female; Humans; Hydrogels; Mice; Mifepristone; Nanostructures; Paclitaxel; Tumor Burden; Xenograft Model Antitumor Assays | 2022 |
Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.
Topics: Breast Neoplasms; Female; Humans; Ki-67 Antigen; Mifepristone; Protein Isoforms; Proteomics; Receptors, Progesterone | 2023 |
Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!
Topics: Breast Neoplasms; Female; Hormone Antagonists; Humans; Mifepristone; Receptors, Progesterone | 2023 |
Targeting progesterone signaling prevents metastatic ovarian cancer.
Topics: Adult; Animals; BRCA1 Protein; Breast; Breast Neoplasms; Cystadenocarcinoma, Serous; Disease Models, Animal; Estradiol; Female; Humans; Mice; Middle Aged; Mifepristone; Mutation; Neoplasms, Experimental; Ovarian Neoplasms; Ovary; Progesterone; Receptors, Progesterone; Salpingo-oophorectomy; Signal Transduction | 2020 |
Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
Topics: Animals; BRCA1 Protein; Breast Neoplasms; Carcinogenesis; Disease Models, Animal; Epithelial Cells; Female; Humans; Mammary Glands, Animal; Mastectomy; Mice; Mifepristone; Norpregnadienes; Receptors, Progesterone; Stromal Cells; Tumor Microenvironment | 2021 |
Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.
Topics: Adult; Aged; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hormone Antagonists; Humans; Immunoblotting; Immunohistochemistry; Middle Aged; Mifepristone; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Progestins; Prognosis; Receptors, Progesterone; Tissue Array Analysis; Treatment Outcome; Tumor Cells, Cultured | 2017 |
Stress hormone-mediated acceleration of breast cancer metastasis is halted by inhibition of nitric oxide synthase.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; DNA Damage; Drug Interactions; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrocortisone; Lung Neoplasms; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mifepristone; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Reactive Nitrogen Species; Reactive Oxygen Species; Stress, Psychological | 2019 |
Fluorescent ligand for human progesterone receptor imaging in live cells.
Topics: Boron Compounds; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Fluorescent Dyes; Hormone Antagonists; Humans; Mifepristone; Models, Molecular; Optical Imaging; Receptors, Progesterone | 2013 |
RU486, a glucocorticoid receptor antagonist, induces apoptosis in U937 human lymphoma cells through reduction in mitochondrial membrane potential and activation of p38 MAPK.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Cytochromes c; Enzyme Activation; Female; HCT116 Cells; Hormone Antagonists; Humans; Leukemia; Lung Neoplasms; Lymphoma; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mifepristone; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Receptors, Glucocorticoid; U937 Cells | 2013 |
The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Female; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Mifepristone; Nanoparticles; Paclitaxel; Protein Isoforms; Receptors, Progesterone; Xenograft Model Antitumor Assays | 2014 |
Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mifepristone; Oligonucleotide Array Sequence Analysis; Paclitaxel; Receptors, Glucocorticoid | 2014 |
Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative study.
Topics: Apoptosis; Breast Neoplasms; Dexamethasone; Estrogens; Female; Glucocorticoids; Hormone Replacement Therapy; Humans; MCF-7 Cells; Medroxyprogesterone Acetate; Mifepristone; Norethindrone; Norethindrone Acetate; Postmenopause; Progesterone Congeners; Receptors, Estrogen; Receptors, Glucocorticoid; Risk; Women's Health | 2014 |
[Inhibitive effects of mifepristone on growth of breast cancer: experiment with animal model].
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Female; Hormone Antagonists; Humans; Immunohistochemistry; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mifepristone; Neovascularization, Pathologic; Random Allocation; Receptors, Estrogen; Receptors, Progesterone; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Dexamethasone; Down-Regulation; Humans; Mifepristone; Mitoxantrone; Neoplasm Proteins; Pregnane X Receptor; Progesterone; Receptors, Glucocorticoid; Receptors, Steroid; Substrate Specificity | 2008 |
Development and validation of an improved inducer-regulator protein complex in the pBRES-regulated expression system.
Topics: Alkaline Phosphatase; Animals; Breast Neoplasms; DNA Primers; Estrenes; Female; Gene Expression Regulation, Neoplastic; Genetic Vectors; Hormone Antagonists; Humans; Luciferases; Mice; Mifepristone; Mutagenesis, Site-Directed; Oximes; Protein Structure, Tertiary; Receptors, Progesterone; Transfection; Transgenes; Tumor Cells, Cultured | 2008 |
Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells.
Topics: Aromatase; Breast Neoplasms; Cell Line, Tumor; Dexamethasone; Gene Expression Regulation, Enzymologic; Glioma; Glucocorticoids; Humans; Mifepristone; Neuroblastoma; Promoter Regions, Genetic; Receptors, Glucocorticoid; Transcription, Genetic; Vitamin D | 2009 |
Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Hormone Antagonists; Humans; Membrane Proteins; Mifepristone; Phosphorylation; Polymerase Chain Reaction; Progesterone; Progestins; Receptors, Progesterone; RNA, Messenger; Serum Albumin, Bovine; Transfection; Vascular Endothelial Growth Factor A | 2009 |
Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Antineoplastic Agents; Apoptosis; Binding, Competitive; Breast Neoplasms; Cell Line, Tumor; Dexamethasone; Down-Regulation; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; HeLa Cells; Humans; Mifepristone; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Receptors, Glucocorticoid; Transcription Factor AP-1; Transcription, Genetic; Triamcinolone; Triterpenes; Ursolic Acid | 2009 |
Progestin stimulation of manganese superoxide dismutase and invasive properties in T47D human breast cancer cells.
Topics: Base Sequence; Breast Neoplasms; Butadienes; Cell Line, Tumor; DNA Primers; Female; Hormone Antagonists; Humans; MAP Kinase Signaling System; Mifepristone; Neoplasm Invasiveness; Nitriles; Progesterone Congeners; Promegestone; Receptors, Progesterone; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Superoxide Dismutase | 2009 |
HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro.
Topics: Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Estradiol; Female; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Hormone Antagonists; Hormones; Humans; Immunoenzyme Techniques; In Vitro Techniques; Middle Aged; Mifepristone; Neoplasm Staging; Progesterone; Prognosis; Survival Rate; T-Lymphocytes, Cytotoxic; Tamoxifen; Tumor Cells, Cultured | 2010 |
The antiproliferative effects of progestins in T47D breast cancer cells are tempered by progestin induction of the ETS transcription factor Elf5.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Female; Humans; Mifepristone; Oligonucleotide Array Sequence Analysis; Progestins; Proto-Oncogene Proteins c-ets; RNA Interference; Transcription Factors | 2010 |
Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.
Topics: Animals; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Separation; Drug Resistance, Neoplasm; Enzyme Activation; Estrogen Receptor alpha; Female; Hormones; Mice; Mice, Inbred BALB C; Mifepristone; Mitogen-Activated Protein Kinase Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptors, Steroid; Signal Transduction | 2010 |
[Reversal effect of mifepristone on adriamycin resistance in human breast cancer cell line MCF-7/ADM in vitro and in vivo].
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Mifepristone; Neoplasm Transplantation; Random Allocation | 2010 |
The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator.
Topics: Active Transport, Cell Nucleus; Androgen Antagonists; Androgens; Aniline Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coprinus; Dexamethasone; Dihydrotestosterone; Down-Regulation; Female; Flutamide; Gene Expression; Genes, Reporter; Humans; Inhibitory Concentration 50; Luciferases; Male; Mifepristone; Nitriles; Plant Extracts; Prostate-Specific Antigen; Prostatic Neoplasms; Quinolines; Receptors, Androgen; Receptors, Glucocorticoid; Tumor Stem Cell Assay; Up-Regulation | 2011 |
MCF-7 cell apoptosis and cell cycle arrest: non-genomic effects of progesterone and mifepristone (RU-486).
Topics: Apoptosis; Breast Neoplasms; Cell Count; Cell Cycle; Cell Line, Tumor; Female; Humans; Mifepristone; Progesterone; Receptors, Progesterone; Uterine Cervical Neoplasms | 2010 |
p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization.
Topics: Breast Neoplasms; Cell Line, Tumor; Endometrial Neoplasms; Female; Gonanes; Humans; Ligands; MAP Kinase Kinase Kinase 1; Mifepristone; Mitogen-Activated Protein Kinase 1; Models, Biological; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Phosphoserine; Promegestone; Proteasome Endopeptidase Complex; Protein Isoforms; Protein Stability; Receptors, Progesterone; Transcription, Genetic | 2011 |
The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; Mifepristone; Receptors, Progesterone; Wnt Signaling Pathway; Wnt1 Protein | 2011 |
Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells.
Topics: Adult; Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Hormone Antagonists; Humans; Leiomyoma; Membrane Proteins; Middle Aged; Mifepristone; Nucleotide Motifs; Oligonucleotide Array Sequence Analysis; Perilipin-2; Position-Specific Scoring Matrices; Receptors, Progesterone; Response Elements; Tumor Cells, Cultured; Uterine Neoplasms | 2012 |
Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Breast Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Hormone Antagonists; Humans; Insulin-Like Growth Factor I; MAP Kinase Kinase 1; Membrane Proteins; Mifepristone; Oxidative Stress; Phosphorylation; Proto-Oncogene Proteins; Reactive Oxygen Species; Receptors, Estrogen; Tamoxifen | 2012 |
Progesterone and levonorgestrel regulate expression of 17βHSD-enzymes in progesterone receptor positive breast cancer cell line T47D.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Line, Tumor; Estrogen Replacement Therapy; Female; Humans; Levonorgestrel; Mifepristone; Progesterone; Receptors, Progesterone | 2012 |
Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line.
Topics: Amphiregulin; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; EGF Family of Proteins; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Heparin-binding EGF-like Growth Factor; Hormone Antagonists; Humans; Intercellular Signaling Peptides and Proteins; Mifepristone; Protein Isoforms; Receptors, Progesterone; Transcriptional Activation | 2012 |
Upregulation of ATBF1 by progesterone-PR signaling and its functional implication in mammary epithelial cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Homeodomain Proteins; Hormone Antagonists; Humans; Mammary Glands, Human; Mice; Mice, Inbred C57BL; Mifepristone; Progesterone; Promoter Regions, Genetic; Receptors, Progesterone; RNA, Small Interfering; Signal Transduction; Stem Cells; Transcriptional Activation; Up-Regulation | 2013 |
Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cytostatic Agents; Female; Hormone Antagonists; Humans; Male; Mifepristone; Neoplasm Invasiveness; Neoplasms; Nervous System Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Time Factors | 2013 |
RU 486: an overview of mifepristone and its potential applications.
Topics: Abortifacient Agents; Abortion, Induced; Americas; Biology; Breast Neoplasms; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptives, Postcoital; Developed Countries; Disease; Embryo Implantation; Endocrine System; Endometrium; Europe; Family Planning Services; France; Genitalia; Genitalia, Female; Hormone Antagonists; Hormones; Labor Stage, First; Menstruation; Mifepristone; Neoplasms; North America; Ovulation; Physiology; Therapeutics; United States; Urogenital System; Uterus | 1993 |
RU 486 research forges on, despite political hurdles.
Topics: Adrenal Cortex; Americas; Biology; Breast Neoplasms; Central Nervous System; Clinical Trials as Topic; Developed Countries; Disease; Economics; Endocrine Glands; Endocrine System; Evaluation Studies as Topic; Financial Management; Financing, Government; Genitalia; Genitalia, Female; Hormone Antagonists; Hormones; Mifepristone; Neoplasms; North America; Physiology; Politics; Prejudice; Research; Social Problems; United States; Urogenital System; Uterus | 1994 |
RU 486 approved in Britain; U.S. research still limited.
Topics: Abortifacient Agents; Abortion, Induced; Americas; Biology; Breast Neoplasms; Consumer Product Safety; Developed Countries; Disease; Endocrine System; Europe; Family Planning Services; France; Hormone Antagonists; Hormones; Legislation as Topic; Mifepristone; Neoplasms; North America; Physiology; Prostaglandins; Scandinavian and Nordic Countries; United Kingdom; United States | 1991 |
Who's trying to scare women?
Topics: Abortion, Induced; Americas; Attitude; Behavior; Biology; Breast Neoplasms; Canada; Contraception; Developed Countries; Disease; Endocrine System; Evaluation Studies as Topic; Family Planning Services; Hormone Antagonists; Hormones; Jurisprudence; Mifepristone; Neoplasms; North America; Physiology; Politics; Psychology; Public Opinion; United States | 1996 |
HDLG5/KIAA0583, encoding a MAGUK-family protein, is a primary progesterone target gene in breast cancer cells.
Topics: Blotting, Northern; Breast Neoplasms; Estrogens; Female; Gene Expression Profiling; Genes, Tumor Suppressor; Guanylate Kinases; Humans; Medroxyprogesterone Acetate; Membrane Proteins; Mifepristone; Nucleoside-Phosphate Kinase; Progestins; Protein Structure, Tertiary; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; src Homology Domains; Tumor Cells, Cultured; Tumor Suppressor Proteins; Up-Regulation | 2002 |
Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Division; Cell Nucleus; Enzyme Inhibitors; Female; Flavonoids; Genes, erbB-2; Hormone Antagonists; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mifepristone; Mitogen-Activated Protein Kinases; Neuregulin-1; Phosphorylation; Receptor, ErbB-2; Receptors, Progesterone; RNA, Messenger; RNA, Neoplasm; Transcriptional Activation; Tumor Cells, Cultured | 2003 |
Repressors of androgen and progesterone receptor action.
Topics: Animals; Binding Sites; Breast Neoplasms; COS Cells; DAX-1 Orphan Nuclear Receptor; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Hormone Antagonists; Humans; Hydroxamic Acids; Male; Metribolone; Mifepristone; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Co-Repressor 2; Promoter Regions, Genetic; Prostate; Prostatic Hyperplasia; Protein Structure, Tertiary; Protein Synthesis Inhibitors; Receptors, Androgen; Receptors, Calcitriol; Receptors, Interferon; Receptors, Progesterone; Receptors, Retinoic Acid; Repressor Proteins; Testosterone Congeners; Tumor Suppressor Protein p53 | 2003 |
Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1.
Topics: Apoptosis; Breast Neoplasms; Caspases; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cytochromes c; Drug Synergism; Drug Therapy, Combination; Estrogen Antagonists; Female; Humans; Mifepristone; Receptors, Estrogen; Retinoblastoma Protein; Tamoxifen; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Cells, Cultured; Tumor Suppressor Proteins; Up-Regulation | 2003 |
Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2.
Topics: Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Hormone Antagonists; Humans; Insulin Receptor Substrate Proteins; Intracellular Signaling Peptides and Proteins; Mifepristone; Phosphoproteins; Progesterone; Progestins; Promegestone; Protein Isoforms; Receptor, Insulin; Receptors, Progesterone; RNA, Messenger; Signal Transduction; Somatomedins; Up-Regulation | 2003 |
Regulation of gene expression by PRA-910, a novel progesterone receptor modulator, in T47D cells.
Topics: Alkaline Phosphatase; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Heterocyclic Compounds, 2-Ring; Humans; Mifepristone; Models, Chemical; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Receptors, Steroid; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2003 |
Progesterone prevents radiation-induced apoptosis in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Chromosome Aberrations; DNA Damage; Female; Gamma Rays; Gene Expression Regulation; Hormone Antagonists; Humans; Micronucleus Tests; Mifepristone; Progesterone; Radiation-Protective Agents; Receptors, Progesterone; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2004 |
Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Coloring Agents; DNA Fragmentation; Drug Resistance, Neoplasm; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Fulvestrant; G1 Phase; Hormone Antagonists; Humans; Immunoblotting; Mifepristone; Phosphorylation; Receptors, Estrogen; Receptors, Progesterone; Resting Phase, Cell Cycle; Tamoxifen; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Isolation of a stromal cell line from an early passage of a mouse mammary tumor line: a model for stromal parenchymal interactions.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Shape; Coculture Techniques; Epidermal Growth Factor; Estradiol; Female; Fibroblasts; Genetic Markers; Hormone Antagonists; Humans; Keratins; Mammary Glands, Animal; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Mifepristone; Mutation; Neoplasm Transplantation; Receptors, Estrogen; Receptors, Progesterone; Stromal Cells; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Suppressor Protein p53 | 2005 |
Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486).
Topics: Breast Neoplasms; Drug Synergism; Estradiol; Female; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Mifepristone; Neoplasms, Hormone-Dependent; Progesterone; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tissue Culture Techniques | 2005 |
Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis.
Topics: Animals; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Dexamethasone; Disease Models, Animal; Female; Gene Expression; Hormone Antagonists; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Mifepristone; Peritoneal Cavity; Phenotype; Proto-Oncogene Mas; Receptor, Macrophage Colony-Stimulating Factor; Up-Regulation | 2005 |
Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance.
Topics: Antibodies; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Endothelial Cells; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression; Histone Acetyltransferases; Humans; Luciferases; Mammary Tumor Virus, Mouse; Mifepristone; Nuclear Receptor Coactivator 1; Phosphatidylinositol 3-Kinases; Progesterone; Promoter Regions, Genetic; Receptors, Progesterone; Recombinant Fusion Proteins; Response Elements; Signal Transduction; Transcription Factors; Transfection; Vascular Endothelial Growth Factor A | 2005 |
Susceptibility of human breast epithelial cells in vitro to hormones and drugs.
Topics: Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Cell Proliferation; Epithelial Cells; Estradiol; Estrogen Antagonists; Female; Humans; Mifepristone; Organ Culture Techniques; Progesterone; Progestins; Tamoxifen | 2006 |
Progesterone regulates HLA-G gene expression through a novel progesterone response element.
Topics: Breast Neoplasms; Cell Line; Cell Line, Tumor; Choriocarcinoma; DNA Primers; Female; Gene Expression Regulation; Genes, Reporter; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Mifepristone; Pregnancy; Progesterone; Promoter Regions, Genetic; Receptors, Progesterone; Uterine Neoplasms | 2006 |
Medicine. Squelching progesterone's signal may prevent breast cancer.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Epithelial Cells; Female; Genes, BRCA1; Genes, p53; Hormone Antagonists; Humans; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mice; Mifepristone; Mutation; Progesterone; Receptors, Progesterone | 2006 |
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Epithelial Cells; Estradiol; Estrous Cycle; Female; Genes, BRCA1; Genes, p53; Hormone Antagonists; Humans; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mice; Mifepristone; Mutation; Phosphorylation; Progesterone; Proteasome Endopeptidase Complex; Receptors, Estrogen; Receptors, Progesterone; RNA, Small Interfering; Ubiquitin | 2006 |
Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Down-Regulation; Estrogen Antagonists; Estrogens; Gene Expression Regulation, Neoplastic; Humans; Mifepristone; Retinoblastoma Protein; RNA, Small Interfering; Tamoxifen | 2007 |
The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner.
Topics: Adenoviridae; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Division; Collagen; Drug Combinations; Female; Fluorescent Antibody Technique; Hormone Antagonists; Humans; Laminin; Ligands; Mifepristone; Neoplasm Invasiveness; Norpregnadienes; Polymerase Chain Reaction; Progesterone; Protein Isoforms; Proteoglycans; Receptors, Progesterone; Transfection; Tumor Cells, Cultured; Wound Healing | 2008 |
Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.
Topics: Angiogenesis Inhibitors; Animals; Aza Compounds; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Growth Processes; Disease Progression; Female; Humans; Medroxyprogesterone Acetate; Mice; Mifepristone; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Progesterone; Progesterone Congeners; Progestins; Receptors, Estrogen; Receptors, Progesterone; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line.
Topics: Base Sequence; Blood; Breast Neoplasms; Cell Division; Charcoal; Culture Media; DNA-Binding Proteins; Down-Regulation; Estradiol; Hormone Antagonists; Humans; Mifepristone; Molecular Sequence Data; Oligodeoxyribonucleotides; Progesterone Congeners; Promegestone; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1995 |
Expression of insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens.
Topics: Breast Neoplasms; Carrier Proteins; Culture Media, Conditioned; Dexamethasone; Estradiol; Estrogen Antagonists; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 4; Insulin-Like Growth Factor Binding Protein 5; Medroxyprogesterone Acetate; Mifepristone; Neoplasm Proteins; Polyunsaturated Alkamides; Pregnenediones; Progesterone; Progestins; Tumor Cells, Cultured | 1994 |
Dissection of progesterone receptor-mediated chromatin remodeling and transcriptional activation in vivo.
Topics: Animals; Breast Neoplasms; Cell Line, Transformed; Cell Transformation, Viral; Chromatin; Female; Gonanes; Humans; Mammary Tumor Virus, Mouse; Mice; Mifepristone; Promoter Regions, Genetic; Receptors, Progesterone; Signal Transduction; Transcriptional Activation | 1995 |
RU 486: an alternative to surgical abortion.
Topics: Abortion, Induced; Breast Neoplasms; Endometrium; Ethics, Professional; Female; Humans; Mifepristone; Patient Education as Topic; Pregnancy | 1994 |
New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
Topics: Base Sequence; Breast Neoplasms; Cyclic AMP; Female; Gonanes; Humans; Mifepristone; Molecular Sequence Data; Progestins; Receptors, Progesterone; Transcription, Genetic; Tumor Cells, Cultured | 1994 |
Effects of the progestin antagonist RU 486 on T-47D breast cancer cell cycle kinetics and cell cycle regulatory genes.
Topics: Breast Neoplasms; Cell Cycle; Cyclin D1; Cyclins; Dose-Response Relationship, Drug; Estradiol; Humans; Mifepristone; Oncogene Proteins; Polyunsaturated Alkamides; Pregnenediones; Progesterone Congeners; Progestins; Proto-Oncogene Proteins c-myc; RNA, Messenger; S Phase; Tumor Cells, Cultured | 1993 |
Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Acetyl Coenzyme A; Breast Neoplasms; Cell Line; DNA-Binding Proteins; Drug Synergism; Ethers, Cyclic; Female; Humans; Kinetics; Mifepristone; Okadaic Acid; Phosphates; Phosphoprotein Phosphatases; Phosphorylation; Receptors, Progesterone; Tetradecanoylphorbol Acetate; Transfection; Tumor Cells, Cultured | 1993 |
The steroid antagonist RU486 exerts different effects on the glucocorticoid and progesterone receptors.
Topics: Animals; Base Sequence; Blotting, Western; Breast Neoplasms; Cell Nucleus; Centrifugation, Density Gradient; Cytosol; DNA; Heat-Shock Proteins; Hormones; Hot Temperature; Humans; Hydrogen-Ion Concentration; Mifepristone; Molecular Sequence Data; Osmolar Concentration; Rats; Receptors, Glucocorticoid; Receptors, Progesterone; Triamcinolone Acetonide; Tumor Cells, Cultured | 1993 |
Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Antineoplastic Agents; Base Sequence; beta-Galactosidase; Breast Neoplasms; Cell Line; Chloramphenicol O-Acetyltransferase; Cyclic AMP; DNA-Binding Proteins; Female; Gonanes; Humans; Mifepristone; Molecular Sequence Data; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Phosphates; Progesterone; Promegestone; Receptors, Progesterone; Recombinant Proteins; Transcription Factors; Transfection; Tumor Cells, Cultured | 1993 |
The constitution of a progesterone response element.
Topics: Baculoviridae; Base Composition; Base Sequence; Binding Sites; Breast Neoplasms; DNA; DNA, Viral; Gene Expression; Humans; Mammary Tumor Virus, Mouse; Mifepristone; Molecular Sequence Data; Mutation; Progestins; Promegestone; Receptors, Progesterone; Transfection; Tumor Cells, Cultured | 1993 |
The relationship between affinity of progestins and antiprogestins for the progesterone receptor in breast cancer cells (ZR-PR-LT) and ability to down-regulate the receptor: evidence for heterospecific receptor modulation via the glucocorticoid receptor.
Topics: Binding, Competitive; Breast Neoplasms; Dexamethasone; Down-Regulation; Female; Gonanes; Humans; Medroxyprogesterone Acetate; Mifepristone; Mitosis; Pregnenediones; Progesterone Congeners; Progestins; Receptors, Glucocorticoid; Receptors, Progesterone; Tumor Cells, Cultured | 1993 |
Isolation of pMGT1: a gene that is repressed by oestrogen and increased by antioestrogens and antiprogestins.
Topics: Breast Neoplasms; DNA, Neoplasm; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mifepristone; Polyunsaturated Alkamides; Progestins; Tamoxifen; Tumor Cells, Cultured | 1993 |
Expression of 67 kDa laminin receptor in human breast cancer cells: regulation by progestins.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Basement Membrane; Blotting, Western; Breast Neoplasms; Cell Adhesion; Female; Fibronectins; Humans; Laminin; Mice; Mice, Nude; Mifepristone; Neoplasm Metastasis; Promegestone; Receptors, Laminin; Reproducibility of Results; Tumor Cells, Cultured; Up-Regulation | 1993 |
Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.
Topics: Base Sequence; Breast Neoplasms; Cell Division; Estradiol; Estrogens; Female; Gene Expression; Humans; In Vitro Techniques; Mifepristone; Molecular Sequence Data; Norgestrel; Norpregnenes; Polyunsaturated Alkamides; Promoter Regions, Genetic; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Transcription, Genetic; Tumor Cells, Cultured | 1993 |
Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.
Topics: Breast Neoplasms; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Cycle; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Cyclins; DNA, Neoplasm; Estradiol; Estrogen Antagonists; Female; G1 Phase; Gene Expression Regulation, Neoplastic; Genes, myc; Growth Substances; Histones; Humans; Insulin; Kinetics; Mifepristone; Polyunsaturated Alkamides; Pregnenediones; Progesterone Congeners; Protein Kinases; Protein Serine-Threonine Kinases; Recombinant Proteins; RNA, Messenger; Time Factors; Transcription, Genetic; Tumor Cells, Cultured | 1993 |
Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Chloramphenicol O-Acetyltransferase; Chromatography, High Pressure Liquid; Estrogen Antagonists; Estrogens; Hormones; Humans; Mifepristone; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; RNA, Messenger; Transforming Growth Factor beta; Tumor Cells, Cultured | 1993 |
Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines.
Topics: Breast Neoplasms; Carcinoma; Cell Division; Desogestrel; Dose-Response Relationship, Drug; Estradiol; Estrenes; Estrogen Antagonists; Female; Furans; Humans; Levonorgestrel; Medroxyprogesterone Acetate; Mifepristone; Nandrolone; Norethindrone; Norpregnenes; Pregnanes; Pregnenediones; Progesterone; Promegestone; Tumor Cells, Cultured | 1995 |
Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor.
Topics: Amino Acid Sequence; Breast Neoplasms; Female; Gonanes; Humans; Mifepristone; Molecular Sequence Data; Phosphorylation; Progestins; Receptors, Progesterone; Signal Transduction; Tumor Cells, Cultured | 1996 |
Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells.
Topics: Androgen Antagonists; Antineoplastic Agents; Binding, Competitive; Breast Neoplasms; Cell Division; Dihydrotestosterone; Estrenes; Flutamide; Gonanes; Humans; Mifepristone; Models, Biological; Progestins; Receptors, Androgen; Transfection; Tumor Cells, Cultured | 1996 |
Effects of sex- and glucocorticoid steroids on breast cancer cells grown as either multicellular tumor spheroids or monolayers.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Division; Dexamethasone; Dihydrotestosterone; Estradiol; Estrogen Antagonists; Humans; Medroxyprogesterone Acetate; Mifepristone; Spheroids, Cellular; Steroids; Tamoxifen; Tumor Cells, Cultured | 1996 |
An amino-terminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity.
Topics: Antineoplastic Agents; Breast Neoplasms; Enhancer Elements, Genetic; Gonanes; HeLa Cells; Hormone Antagonists; Humans; Methionine; Mifepristone; Progesterone Congeners; Progestins; Promegestone; Protein Biosynthesis; Receptors, Progesterone; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1996 |
Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Drug Resistance; Estrenes; Furans; Hormone Antagonists; Humans; Mifepristone; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Oncogene Proteins; Phosphorylation; Progestins; Protein Processing, Post-Translational; Recombinant Fusion Proteins; Retinoblastoma Protein; Tumor Cells, Cultured | 1997 |
Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays.
Topics: Adenocarcinoma; Alkaline Phosphatase; Androgen Antagonists; Androgens; Breast Neoplasms; Cyproterone Acetate; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Flutamide; Gonanes; Humans; Mifepristone; Polyunsaturated Alkamides; Progestins; Tamoxifen; Testosterone; Testosterone Congeners; Tumor Cells, Cultured | 1997 |
Clinical pharmacokinetics of mifepristone.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Breast Neoplasms; Contraception; Endometriosis; Female; Humans; Labor, Induced; Leiomyoma; Meningioma; Mifepristone; Pregnancy; Progestins | 1997 |
Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1).
Topics: Breast Neoplasms; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cyclin A; Cyclin B; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; G1 Phase; Gene Expression Regulation; Gonanes; Hormone Antagonists; Humans; Microtubule-Associated Proteins; Mifepristone; Progesterone; Promegestone; Protein Serine-Threonine Kinases; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1997 |
Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Topics: Breast Neoplasms; Endometrial Neoplasms; Endothelial Growth Factors; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphokines; Medroxyprogesterone Acetate; Megestrol Acetate; Mifepristone; Neoplasm Proteins; Neovascularization, Pathologic; Norethindrone; Norethynodrel; Norgestrel; Progesterone; Progestins; Receptors, Progesterone; Stimulation, Chemical; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
Interference between progesterone and dioxin signal transduction pathways. Different mechanisms are involved in repression by the progesterone receptor A and B isoforms.
Topics: Breast Neoplasms; Cytochrome P-450 CYP1A1; Female; Gene Expression Regulation, Enzymologic; Gonanes; Hormone Antagonists; Humans; Mifepristone; Polychlorinated Dibenzodioxins; Pregnenediones; Progesterone Congeners; Receptors, Aryl Hydrocarbon; Receptors, Progesterone; Recombinant Proteins; Signal Transduction; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Up-Regulation | 1998 |
Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers.
Topics: Breast Neoplasms; Cell Division; Cytosol; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Gonanes; Hormone Antagonists; Humans; Mifepristone; Pregnenediones; Progestins; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1997 |
Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gonanes; Hormone Antagonists; Humans; Mice; Mice, Nude; Mifepristone; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1998 |
Modulation of androgen and progesterone receptors by phytochemicals in breast cancer cell lines.
Topics: Beverages; Breast Neoplasms; Chamomile; Estrogen Antagonists; Female; Flavanones; Flavonoids; Fruit; Gallic Acid; Humans; Imidazoles; Mifepristone; Nitriles; Oils, Volatile; Plant Extracts; Plants, Medicinal; Prostate-Specific Antigen; Receptors, Androgen; Receptors, Progesterone; Transcription, Genetic; Tumor Cells, Cultured; Vegetables | 1998 |
Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen.
Topics: Alitretinoin; Animals; Anticarcinogenic Agents; Apoptosis; Benzoates; Bexarotene; Breast Neoplasms; Cell Division; Disease Models, Animal; Female; Fenretinide; Hormone Antagonists; Humans; Mammary Neoplasms, Animal; Mice; Mice, Inbred C57BL; Mifepristone; Retinoids; Tamoxifen; Tetrahydronaphthalenes; Tretinoin; Tumor Cells, Cultured | 1998 |
Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; DNA Fragmentation; Down-Regulation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Hormone Antagonists; Humans; Mifepristone; Neoplasms, Hormone-Dependent; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Tamoxifen; Transforming Growth Factor beta; Tumor Cells, Cultured | 1998 |
Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Ceramides; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Estrogen Antagonists; Female; Hormone Antagonists; Humans; Mifepristone; Tamoxifen; Tumor Cells, Cultured | 1999 |
Reduced expression of endothelial and inducible nitric oxide synthase in a human breast cancer cell line which has acquired estrogen independence.
Topics: Animals; Breast Neoplasms; Cattle; Estrogens; Female; Humans; Immunohistochemistry; Mifepristone; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Progesterone; Rabbits; Tamoxifen; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1999 |
Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells.
Topics: Blotting, Western; Breast Neoplasms; Cell Division; Charcoal; Culture Media; Electrophoresis, Polyacrylamide Gel; Estradiol; Female; Gonanes; Hormone Antagonists; Humans; Mifepristone; Phosphorylation; Progesterone Congeners; Promegestone; Receptors, Progesterone; Tumor Cells, Cultured | 1999 |
Selective activation of the glucocorticoid receptor by steroid antagonists in human breast cancer and osteosarcoma cells.
Topics: Animals; Breast Neoplasms; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Glucocorticoids; Hormone Antagonists; Humans; Hydroxycorticosteroids; Mammary Tumor Virus, Mouse; Mice; Mifepristone; Osteosarcoma; Promoter Regions, Genetic; Receptors, Glucocorticoid; Transcription, Genetic; Tumor Cells, Cultured | 2000 |
Progestin regulation of 11beta-hydroxysteroid dehydrogenase expression in T-47D human breast cancer cells.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Breast Neoplasms; Carcinoma; Corticosterone; Dose-Response Relationship, Drug; Estradiol; Estrone; Female; Gene Expression Regulation, Enzymologic; Humans; Hydroxysteroid Dehydrogenases; Medroxyprogesterone Acetate; Mifepristone; NAD; Progesterone Congeners; Progestins; RNA, Messenger; Tumor Cells, Cultured | 2000 |
Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mifepristone; Progestins; Prostate-Specific Antigen; Proteins; Receptors, Estrogen; Receptors, Progesterone; Tissue Kallikreins; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |
Effect of mifepristone approval on research remains to be seen.
Topics: Abortifacient Agents, Steroidal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Female; France; Germany; Humans; Male; Mifepristone; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Progesterone; Prostatic Neoplasms; Research Support as Topic; Tamoxifen; United States; United States Food and Drug Administration | 2000 |
Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity.
Topics: Alkaline Phosphatase; Animals; Breast Neoplasms; Cell Division; Cell Transformation, Neoplastic; DNA-Binding Proteins; Endometrium; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Levonorgestrel; Macaca fascicularis; Mifepristone; Ovulation; Piperazines; Piperidines; Progesterone; Protein Binding; Pyridazines; Rabbits; Receptors, Androgen; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Progesterone; Substrate Specificity; Tumor Cells, Cultured | 2000 |
Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1.
Topics: Animals; Apoptosis; Breast; Breast Neoplasms; Cell Line; Cell Survival; Dexamethasone; Enzyme Induction; Epithelial Cells; Female; Gene Expression Regulation, Enzymologic; Glucocorticoids; Growth Substances; Humans; Immediate-Early Proteins; Mifepristone; Nuclear Proteins; Protein Serine-Threonine Kinases; Rats; Receptors, Glucocorticoid; Transcription, Genetic | 2001 |
Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells.
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Blotting, Northern; Breast Neoplasms; Culture Media; Dactinomycin; Dose-Response Relationship, Drug; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Estrogens; Glucocorticoids; Hormone Antagonists; Humans; Lymphokines; Medroxyprogesterone Acetate; Mifepristone; Progesterone; Progestins; Protein Isoforms; Protein Synthesis Inhibitors; Puromycin; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Differential regulation of retinoblastoma protein by hormonal and antihormonal agents in T47D breast cancer cells.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Estrogens; Fulvestrant; Gonanes; Humans; Mifepristone; Phosphorylation; Progesterone; Promegestone; Receptors, Estrogen; Receptors, Progesterone; Retinoblastoma Protein; Tumor Cells, Cultured | 2001 |
Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cell Size; Enzyme Activation; Female; Focal Adhesions; Gonanes; Hormone Antagonists; Humans; MAP Kinase Signaling System; Mifepristone; Progesterone; Receptors, Progesterone; Recombinant Fusion Proteins; Stress Fibers; Transfection; Tumor Cells, Cultured | 2001 |
Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor.
Topics: Baculoviridae; Biopolymers; Breast Neoplasms; DNA-Binding Proteins; Humans; Mifepristone; Precipitin Tests; Promegestone; Receptors, Progesterone; Recombinant Proteins; Tumor Cells, Cultured | 1992 |
Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody.
Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antibody Specificity; Binding Sites; Blotting, Western; Breast Neoplasms; Chickens; Cytosol; Female; Humans; Ligands; Mifepristone; Molecular Sequence Data; Molecular Weight; Oviducts; Peptides; Protein Conformation; Receptors, Progesterone; Tumor Cells, Cultured | 1992 |
Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line.
Topics: Breast Neoplasms; Carcinoma; Cell Count; Cell Cycle; Cell Division; DNA, Neoplasm; Drug Combinations; Humans; Mifepristone; Osmolar Concentration; Tamoxifen; Tumor Cells, Cultured | 1992 |
Androgen regulation of prolactin-receptor gene expression in MCF-7 and MDA-MB-453 human breast cancer cells.
Topics: Androgens; Breast Neoplasms; Dihydrotestosterone; Female; Gene Expression Regulation; Humans; Mifepristone; Pregnenediones; Receptors, Prolactin; RNA, Messenger; Tumor Cells, Cultured | 1992 |
Induction of calcitonin receptor expression by glucocorticoids in T47D human breast cancer cells.
Topics: Breast Neoplasms; Calcitonin; Carcinoma, Intraductal, Noninfiltrating; Cyclic AMP; Dexamethasone; Female; Gene Expression Regulation; Humans; Hydrocortisone; Mifepristone; Protein Binding; Receptors, Calcitonin; Receptors, Cell Surface; Time Factors; Tumor Cells, Cultured | 1991 |
Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.
Topics: Blotting, Northern; Breast Neoplasms; Cell Cycle; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Kinetics; Mifepristone; Pregnenediones; Progesterone Congeners; Proto-Oncogene Mas; Proto-Oncogene Proteins c-fos; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1991 |
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines.
Topics: Breast Neoplasms; Estrogen Antagonists; Estrogens; Humans; Mifepristone; Neoplasms, Hormone-Dependent; Progestins; Prognosis; Promegestone; Proto-Oncogene Proteins; Pyrrolidines; Receptor, ErbB-2; RNA, Messenger; RNA, Neoplasm; Thiophenes; Tumor Cells, Cultured | 1990 |
Progestin stimulation of thymidine kinase in the human breast cancer cell line T47D.
Topics: Breast Neoplasms; Cell Division; Dactinomycin; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Mifepristone; Progestins; Promegestone; Thymidine Kinase; Time Factors; Tumor Cells, Cultured | 1991 |
RU-486. Drug debate expands.
Topics: Biomedical Research; Breast Neoplasms; Cushing Syndrome; Federal Government; Government Regulation; Humans; Internationality; Mifepristone; Research; Risk Assessment; United States; United States Food and Drug Administration | 1990 |
Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor.
Topics: Animals; Binding Sites; Breast Neoplasms; Cell Line; Chickens; Chromosome Deletion; Female; Gene Expression Regulation; HeLa Cells; Humans; Mifepristone; Mutagenesis, Site-Directed; Progesterone; Promoter Regions, Genetic; Receptors, Progesterone; Transcription, Genetic; Transfection | 1990 |
Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells.
Topics: Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carrier Proteins; Cell Division; Drug Interactions; Estradiol; Flutamide; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Membrane Transport Proteins; Mifepristone; Neoplasm Proteins; Promegestone; Tumor Cells, Cultured | 1990 |
Treatment of breast cancer with different antiprogestins: preclinical and clinical studies.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hormones; Humans; Middle Aged; Mifepristone; Organ Size; Rats; Receptors, Steroid; Tamoxifen | 1990 |
Sex steroid hormone modulation of NADPH pathways in MCF-7 cells.
Topics: Breast Neoplasms; Cell Division; Drug Interactions; Estradiol; Glucosephosphate Dehydrogenase; Humans; Mifepristone; NADP; Norpregnadienes; Premedication; Promegestone; Tamoxifen; Tumor Cells, Cultured | 1990 |
Progestin stimulation of lactate dehydrogenase in the human breast cancer cell line T-47D.
Topics: Breast Neoplasms; Cell Line; Estrenes; Female; Humans; L-Lactate Dehydrogenase; Mifepristone; Neoplasm Proteins; Progestins; Promegestone; RNA | 1987 |
Receptor binding of NBD-labeled fluorescent estrogens and progestins in whole cells and cell-free preparations.
Topics: Affinity Labels; Binding, Competitive; Breast Neoplasms; Cell Line; Cell Nucleus; Cytoplasm; Estradiol; Estrenes; Fluorescent Dyes; Hexestrol; Humans; Mifepristone; Nafoxidine; Oxadiazoles; Promegestone; Receptors, Estrogen; Receptors, Progesterone; Spectrometry, Fluorescence; Tumor Cells, Cultured | 1989 |
Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors.
Topics: Acetates; Breast Neoplasms; Dihydrotestosterone; Dose-Response Relationship, Drug; Fatty Acids; Flutamide; Humans; In Vitro Techniques; Lipid Metabolism; Microscopy, Electron; Mifepristone; Norpregnadienes; Promegestone; Receptors, Androgen; Receptors, Progesterone; Triglycerides; Tumor Cells, Cultured | 1989 |
Growth stimulation of T47D human breast cancer cells by the anti-progestin RU486.
Topics: Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estrenes; Humans; Mifepristone; Progestins; Tumor Cells, Cultured | 1989 |
Antiprogestins, a new form of endocrine therapy for human breast cancer.
Topics: Aged; Androstenedione; Breast Neoplasms; Drug Evaluation; Estradiol; Estrenes; Female; Humans; Hydrocortisone; Lymphatic Metastasis; Middle Aged; Mifepristone | 1989 |
Effects of progestins, estrogens, and antihormones on growth and lactate dehydrogenase in the human breast cancer cell line T47D.
Topics: Breast Neoplasms; Cell Division; Estrenes; Estrogens; Hormone Antagonists; Humans; L-Lactate Dehydrogenase; Mifepristone; Progestins; Promegestone; Tumor Cells, Cultured | 1989 |
Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors.
Topics: Breast Neoplasms; Cell Line; Epidermal Growth Factor; Estradiol; Estrenes; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation; Humans; Insulin-Like Growth Factor I; Mifepristone; Norpregnadienes; Promegestone; Protein Biosynthesis; Receptors, Estrogen; RNA, Messenger; Somatomedins; Tumor Cells, Cultured | 1989 |
Comparative effects of 17 beta-estradiol, progestin R5020, tamoxifen and RU38486 on lactate dehydrogenase activity in MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Line; Dexamethasone; Dihydrotestosterone; Estradiol; Estrenes; Female; Histocytochemistry; Humans; L-Lactate Dehydrogenase; Mifepristone; Norpregnadienes; Promegestone; Tamoxifen | 1989 |
Immunocytochemical localization of progesterone receptors in breast cancer with anti-human receptor monoclonal antibodies.
Topics: Antibodies, Monoclonal; Antibody Specificity; Breast Neoplasms; Carcinoma; Cell Nucleus; Cytosol; Estrenes; Female; Humans; Immunohistochemistry; Mifepristone; Molecular Weight; Promegestone; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Progesterone | 1988 |
Comment on 'Difference between R5020 and the anti progestin RU486 in antiproliferative effects on human breast cancer cells'.
Topics: Breast Neoplasms; Cell Division; Estrenes; Humans; Mifepristone; Norpregnadienes; Promegestone | 1988 |
Steroid hormone-dependent interaction of human progesterone receptor with its target enhancer element.
Topics: Breast Neoplasms; Cell Line; Enhancer Elements, Genetic; Estradiol; Estrenes; Female; Humans; Hydrocortisone; Mifepristone; Progesterone; Promegestone; Receptors, Progesterone; Tumor Cells, Cultured | 1988 |
Epidermal growth factor gene expression in human breast cancer cells: regulation of expression by progestins.
Topics: Breast Neoplasms; Epidermal Growth Factor; Estrenes; Female; Gene Amplification; Gene Expression Regulation; Humans; Mifepristone; Progestins; RNA, Messenger; Tumor Cells, Cultured | 1988 |
Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines.
Topics: Breast Neoplasms; Estrenes; Estrogen Antagonists; Estrogens; Female; Humans; Ligands; Mifepristone; Promegestone; Receptors, Progesterone; RNA, Messenger; Tumor Cells, Cultured | 1988 |
Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Estradiol; Estrenes; Glucocorticoids; Humans; Mifepristone; Norpregnadienes; Phenolsulfonphthalein; Promegestone; Protein Biosynthesis; Receptors, Estrogen; Tumor Cells, Cultured | 1987 |
Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells.
Topics: Breast Neoplasms; Cell Survival; Estradiol; Estrenes; Estrogen Antagonists; Female; Humans; Mifepristone; Progestins; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1987 |
Antiprogestin-receptor complexes: differences in the interaction of the antiprogestin RU38,486 and the progestin R5020 with the progesterone receptor of human breast cancer cells.
Topics: Binding, Competitive; Breast Neoplasms; Cell Line; Centrifugation, Density Gradient; Deoxyribonucleases; Estrenes; Female; Humans; Mifepristone; Norpregnadienes; Promegestone; Receptors, Progesterone; Ribonucleases; Sulfhydryl Compounds; Urea | 1986 |
RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor.
Topics: Breast Neoplasms; Cell Division; Cell Line; Electrophoresis, Polyacrylamide Gel; Estrenes; Glucocorticoids; Humans; Mifepristone; Neoplasm Proteins; Progestins; Receptors, Glucocorticoid; Receptors, Progesterone | 1985 |
The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells.
Topics: Affinity Labels; Breast Neoplasms; Cells, Cultured; Estrenes; Estrogens; Female; Humans; Mifepristone; Progestins; Promegestone; Receptor, Insulin; Receptors, Glucocorticoid; Receptors, Progesterone | 1985 |